Loading clinical trials...
Loading clinical trials...
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years
Conditions
Interventions
Baricitinib
Placebo
Locations
107
United States
Tallahassee Memorial HealthCare
Tallahassee, Florida, United States
University of South Florida
Tampa, Florida, United States
University of Iowa
Iowa City, Iowa, United States
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
Novak Center for Children's Health
Louisville, Kentucky, United States
Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania, United States
Start Date
January 12, 2026
Primary Completion Date
July 1, 2031
Completion Date
July 1, 2031
Last Updated
April 17, 2026
NCT06807190
NCT07160816
NCT04786262
NCT06748963
NCT03648918
NCT06329375
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions